The new normal in healthcare:
Galen / Atlantica is a boutique healthcare firm that enables corporate and institutional leaders to navigate “the new normal” and play a leadership role beyond their traditional borders.
We believe that investment in innovation can and should enhance health system efficiency, while improving patient outcomes.
We map and understand the complex set of interactions that drive value for individual institutions and society. We work across silos to integrate insight, formulate strategy, and effect change. And we draw on our experience leading multiple collaborations of senior leaders in government, industry, and civil society, bringing this network to bear in addressing complex global challenges.
Matt’s focus on the intersection of business and public policy has provided exciting opportunities to shape the agenda for economic, organizational, and social change on four continents. He believes that cross-sector leadership can best address society’s biggest challenges.
Matt’s career spans service as a Peace Corps Volunteer in Africa, as an investment banker focused on the technology sector, a strategy consultant at BCG, and a partner at Tapestry Networks. At Tapestry, he focused on aligning private sector innovation with public need. Matt has an undergraduate business degree from UC Berkeley and a masters in public policy from Harvard’s Kennedy School.
Prior to founding Galen/Atlantica, Nicholas was a partner at Tapestry Networks, where he led working collaborations among healthcare leaders from industry, government and civil society. He started his career as an environmental and energy lawyer in Washington DC with Latham & Watkins, and then worked as strategy consultant in Europe and the Middle East with McKinsey, and as head of the chairman and CEO’s office of a $5 billion ICT company.
He holds a BS in systems engineering from the University of Virginia, a Master’s in technology policy from MIT, and a JD from Harvard Law School.
In many clinical situations doctors need to treat patients with antibiotics without knowing what is causing their symptoms. This leads to widespread use of antibiotics where they are not needed, and the risk of using the wrong antibiotic where one is needed.
The widespread adoption of faster and more accurate diagnostics would address this problem, but their development and introduction has been slow. Part of what’s missing has been a way to clearly define the different jobs to be done by diagnostics and the target performance characteristics they need to deliver.
The workshop also identified four distinct diagnostic typologies n infectious disease, along with the different performance characteristics required from each category. This much-needed specificity serves as a roadmap for clinicians, patients, technology developers, and policy-makers.
Copyright © 2015 Galen-Atlantica